Revelyx Bio

Revelyx Bio is a company established in 2025 in Delaware, USA. It has entered into an exclusive licensing agreement with a Chinese Biotech for its self-developed recombinant Type A botulinum toxin liquid formulation pipeline, granting it exclusive licensing rights to the licensed product in overseas markets excluding mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region.